With 11% of clinical research sites failing to enroll a single patient, and 37% of sites under-enrolling, the need for improved efficiency is evident. Studies involving fewer sites have potential to improve on this performance, taking advantage of the best leaders in each therapeutic area, reducing travel and administrative costs, and aligning processes for easier start-up.
This insight brief examines IQVIA’s innovative approaches to patient and site engagement, such as pioneering early planning, innovative partnerships, new technology and communication tools, working with patient advocacy groups, precision enrollment and the IQVIA Infosario Site Gateway platform.
Introduction
大约11％的研究站点全行业未能招募一名患者，其中37％的网站不足，效率低下并失去了生产力。1这代表了浪费时间和金钱，从而使赞助商或其他研究利益相关者都受益。涉及较少站点的研究有可能改善这种表现，利用每个治疗领域的最佳领导者，降低旅行和行政成本，并使流程保持一致，以便于启动。
Studies involving fewer sites hold promise in improving clinical trial efficiency, drawing on the expertise of therapeutic experts, minimizing costs and optimizing processes for easier start-up.
早期计划是试验成功的主要因素 - 包括确定每个国家 /地区的患者途径，了解患者和研究者的观点，并将这些见解应用于试验设计和实施。betway必威怎么提款患者倡导小组是有关患者偏好的重要信息来源，有助于为研究设计和量身定制的沟通计划以及标志潜在的入学和保留风险提供信息。对于极少数情况，还可以使用社交听力工具来开采患者生成的内容的在线来源，以帮助了解患者如何体验特定状况。早期与网站，临床和医疗团队以及国内监管专家的交战对于成功的入学计划也至关重要。
此洞察摘要通过改进的患者和现场参与度检查了新的和创新的解决方案，以更快地向患者获取药物。